• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膀胱癌的当代管理:识别有风险的患者。

Contemporary Management of Bladder Cancer: Identifying patients who are at risk.

出版信息

Can Fam Physician. 1991 Jun;37:1469-77.

PMID:21229043
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2145394/
Abstract

Bladder cancer is currently the fifth most common cancer in Western society, and its incidence appears to be increasing. Important advances have recently occurred in both diagnostic and therapeutic approaches to bladder neoplasms. Presentation is not unique, and physician awareness is important to identify patients who are at risk for bladder neoplasia and consequently require further investigation. A diagnostic approach and contemporary management are discussed.

摘要

膀胱癌目前是西方社会中第五大常见癌症,其发病率似乎在上升。最近在膀胱癌的诊断和治疗方法上都取得了重要进展。其表现并不具有独特性,因此医生的意识对于识别有膀胱癌风险的患者并因此需要进一步检查非常重要。本文讨论了诊断方法和现代治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6481/2145394/b49f18a602ab/canfamphys00136-0140-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6481/2145394/e2532802d983/canfamphys00136-0137-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6481/2145394/b49f18a602ab/canfamphys00136-0140-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6481/2145394/e2532802d983/canfamphys00136-0137-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6481/2145394/b49f18a602ab/canfamphys00136-0140-a.jpg

相似文献

1
Contemporary Management of Bladder Cancer: Identifying patients who are at risk.膀胱癌的当代管理:识别有风险的患者。
Can Fam Physician. 1991 Jun;37:1469-77.
2
Neoplasia in adult exstrophy patients.
BJU Int. 2001 May;87(7):623-8. doi: 10.1046/j.1464-410x.2001.02136.x.
3
New horizons in bladder cancer research.膀胱癌研究的新视野。
Urol Oncol. 2020 Dec;38(12):867-885. doi: 10.1016/j.urolonc.2018.12.014. Epub 2019 Mar 7.
4
The impact of contemporary bladder management techniques on struvite calculi associated with spinal cord injury.当代膀胱管理技术对与脊髓损伤相关的鸟粪石结石的影响。
BJU Int. 1999 Aug;84(3):280-5.
5
Bladder cancer.膀胱癌
Curr Opin Oncol. 2005 May;17(3):275-80. doi: 10.1097/01.cco.0000156985.47984.9e.
6
Metabonomic profiling of bladder cancer.膀胱癌的代谢组学分析
J Proteome Res. 2015 Feb 6;14(2):587-602. doi: 10.1021/pr500966h. Epub 2014 Nov 26.
7
Considerations on the use of diagnostic markers in management of patients with bladder cancer.关于诊断标志物在膀胱癌患者管理中的应用的思考。
World J Urol. 2008 Feb;26(1):39-44. doi: 10.1007/s00345-007-0232-1. Epub 2007 Dec 19.
8
Highlights from the Society of Urologic Oncology, 5th Annual Meeting, December 3-4, 2004, Bethesda, Maryland, United States of America.美国泌尿外科肿瘤学会第五届年会亮点,2004年12月3日至4日,美国马里兰州贝塞斯达。
J Urol. 2005 Dec;174(6):2330-3. doi: 10.1097/01.ju.0000181828.95803.94.
9
Bladder cancer. Management of an increasingly common tumor.膀胱癌。一种日益常见肿瘤的管理。
Postgrad Med. 1983 Mar;73(3):139-51. doi: 10.1080/00325481.1983.11697800.
10
Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer.用于膀胱癌早期检测、治疗效果评估及复发监测的遗传和表观遗传生物标志物。
Rev Med Chir Soc Med Nat Iasi. 2011 Jan-Mar;115(1):163-7.

本文引用的文献

1
Superficial bladder cancer: progression and recurrence.浅表性膀胱癌:进展与复发
J Urol. 1983 Dec;130(6):1083-6. doi: 10.1016/s0022-5347(17)51695-x.
2
The biology and treatment of superficial bladder cancer.浅表性膀胱癌的生物学特性与治疗
J Clin Oncol. 1984 May;2(5):505-31. doi: 10.1200/JCO.1984.2.5.505.
3
The impact of cigarette smoking on stage, grade and number of recurrences of transitional cell carcinoma of the bladder.
J Urol. 1987 Mar;137(3):401-3. doi: 10.1016/s0022-5347(17)44048-1.
4
Toxicity of intravesical BCG and its management in patients with superficial bladder tumors.膀胱内卡介苗灌注治疗浅表性膀胱肿瘤的毒性反应及其处理
Cancer. 1987 Aug 1;60(3):326-33. doi: 10.1002/1097-0142(19870801)60:3<326::aid-cncr2820600309>3.0.co;2-5.
5
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.M-VAC方案(甲氨蝶呤、长春花碱、阿霉素和顺铂)用于晚期尿路上皮移行细胞癌。
J Urol. 1988 Mar;139(3):461-9. doi: 10.1016/s0022-5347(17)42494-3.
6
Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies.由小鼠单克隆抗体所界定的人类浅表膀胱肿瘤抗原的多态性表达
Proc Natl Acad Sci U S A. 1987 Oct;84(20):7227-31. doi: 10.1073/pnas.84.20.7227.
7
A newer form of bladder substitute based on historical perspectives.基于历史视角的一种新型膀胱替代物。
Semin Urol. 1988 Feb;6(1):57-65.
8
Treatment of diffuse transitional cell carcinoma in situ by whole bladder hematoporphyrin derivative photodynamic therapy.全膀胱血卟啉衍生物光动力疗法治疗弥漫性原位移行细胞癌
J Urol. 1985 Oct;134(4):675-8. doi: 10.1016/s0022-5347(17)47379-4.
9
Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder.血卟啉衍生物光动力疗法治疗膀胱浅表移行细胞癌
N Engl J Med. 1987 Nov 12;317(20):1251-5. doi: 10.1056/NEJM198711123172003.
10
A comparative study of the ileal conduit, Kock pouch and modified Indiana pouch.回肠导管、科克袋和改良印第安纳袋的比较研究。
J Urol. 1989 Nov;142(5):1193-6. doi: 10.1016/s0022-5347(17)39026-2.